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A patient-derived xenograft pre-clinical trial
reveals treatment responses and a
resistance mechanism to karonudib in
metastatic melanoma
Berglind O. Einarsdottir1, Joakim Karlsson 2, Elin M. V. Söderberg1, Mattias F. Lindberg1, Elisa Funck-Brentano1,
Henrik Jespersen1, Siggeir F. Brynjolfsson 3, Roger Olofsson Bagge1, Louise Carstam4, Martin Scobie5,
Tobias Koolmeister5, Olof Wallner5, Ulrika Stierner1, Ulrika Warpman Berglund5, Lars Ny1, Lisa M. Nilsson1, Erik Larsson2,
Thomas Helleday5 and Jonas A. Nilsson1
Abstract
Karonudib (TH1579) is a novel compound that exerts anti-tumor activities and has recently entered phase I clinical
testing. The aim of this study was to conduct a pre-clinical trial in patient-derived xenografts to identify the possible
biomarkers of response or resistance that could guide inclusion of patients suffering from metastatic melanoma in
phase II clinical trials. Patient-derived xenografts from 31 melanoma patients with metastatic disease were treated with
karonudib or a vehicle for 18 days. Treatment responses were followed by measuring tumor sizes, and the models
were categorized in the response groups. Tumors were harvested and processed for RNA sequencing and protein
analysis. To investigate the effect of karonudib on T-cell-mediated anti-tumor activities, tumor-infiltrating T cells were
injected in mice carrying autologous tumors and the mice treated with karonudib. We show that karonudib has
heterogeneous anti-tumor effect on metastatic melanoma. Thus, based on the treatment responses, we could divide
the 31 patient-derived xenografts in three treatment groups: progression group (32%), suppression group (42%), and
regression group (26%). Furthermore, we show that karonudib has anti-tumor effect, irrespective of major melanoma
driver mutations. Also, we identify high expression of ABCB1, which codes for p-gp pumps as a resistance biomarker.
Finally, we show that karonudib treatment does not hamper T-cell-mediated anti-tumor responses. These findings can
be used to guide future use of karonudib in clinical use with a potential approach as precision medicine.
Introduction
Cutaneous melanoma is the most aggressive form of
skin cancer and is often fatal in metastatic stages1. Recent
advances in melanoma genetics and how melanoma cells
escape immune attack have resulted in the development
of targeted therapies inhibiting the MAPK pathway as well
as immunotherapies. These treatments have improved the
overall survival and sometimes have resulted in patients
possibly being cured from their disease2. Despite these
successes, new treatments are needed, since the majority
of patients are still not cured.
The recently developed inhibitor, karonudib (TH1579),
was designed to inhibit the oxidized nucleotide-sanitizing
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Fig. 1 (See legend on next page.)
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enzyme, MTH1 (encoded by NUDT1)3, 4. The compound
has shown promising anti-tumor effect both in vitro and
in vivo4 and has initiated phase I clinical testing in cancer
patients with advanced solid malignancies
(NCT03036228). Lately, known anti-cancer effects, such
as microtubule inhibition, have been proposed for com-
pounds containing the same scaffold as karonudib
(TH588 and TH287) (unpublished observations)5–7. The
exact mechanism of action of karonudib and the possible
role of MTH1 in cancer is therefore under investigation.
Regardless of the mechanism of action of the com-
pound, karonudib exhibits good cytotoxic effect in cancer
cells both in vitro and in vivo, while being well tolerated in
non-transformed cells3, 4. However, the extent of inter-
patient heterogeneity of the cytotoxic effect has not been
determined. Furthermore, no predictive biomarkers of
response have been identified. These could be used to
identify which patients may benefit the most from this
treatment and which patients may be spared. Lastly, given
the recent successes of immunotherapies in melanoma,
karonudib needs to be assessed for its potential impact on
T-cell immunity. Here we made use of our melanoma
PDX platform8 and a novel immune oncology PDX
model9 to assess the heterogeneous responses observed
when treating metastatic melanoma tumors in multiple
patients with karonudib. We show that karonudib has
anti-tumor effect in a majority of PDX models, but some
PDX models remain unaffected, which in some cases can
be attributed to known anti-cancer drug resistance
mechanisms. Reassuringly though, we also demonstrate
that karonudib treatment does not hamper cytotoxic T-
cell anti-tumor activities.
Results
Heterogeneous response to karonudib treatment in
melanoma PDXes
We have previously shown that TH588 and karonudib
can inhibit the tumor growth of one of our PDX models3, 4.
However, the heterogeneous responses of metastatic
melanoma have not been modeled. To that end, we
designed a pre-clinical PDX trial consisting of tumor
samples from 31 metastatic melanoma patients repre-
senting models of most subtypes (Supplemental table 1).
All samples had been serially transplanted in NOG mice
as previously described8. Each sample was transplanted in
three mice, and the two fastest growing xenografts were
divided into two treatment groups, thus utilizing one
mouse per patient per treatment group (1 × 1 × 1) as
previously described10. The groups were treated with
either 90mg/kg karonudib or with the vehicle. All mice
tolerated the treatment, as evidenced by their stable
weights throughout the treatment (Supplemental fig-
ures S2-S4). After 3 weeks of treatment, the mice were
sacrificed and tumors were harvested. A piece from each
tumor was embedded in paraffin for immunohistochem-
ical staining analysis, and a piece of each vehicle-treated
tumor was RNA sequenced for mutation and expression
analysis (Fig. 1a).
After 3 weeks of treatment, heterogeneous responses to
karonudib treatment were observed for the 31 PDX
models (Fig. 1b and Supplemental figure S1-S4). Twenty-
six percent (8/31) of the PDX models were regressed
during karonudib treatment and thus, were categorized as
the regression group. Forty-two percent (13/31) of the
PDX models responded to karonudib treatment by
reduced growth, compared with vehicle-treated tumors,
and were categorized as the suppression group. Interest-
ingly though, 32% (10/31) of the PDX models did not
exhibit any reduced growth of karonudib-treated tumors,
compared with vehicle; these were therefore categorized
as the progression group.
To further investigate the treatment responses, the
growth of each karonudib-treated PDX was compared
with the growth of its matching vehicle-treated PDX
(Fig. 1c–e). A significant difference in growth speed of the
vehicle-treated PDXes was observed between the response
groups, where the fastest growing PDXes were found in
the suppression group. Furthermore, statistically sig-
nificant difference was observed in the probability of
progression-free survival (PFS), as based on tumor dou-
bling time between the groups (p= 0.0039) (Fig. 1f). This
markedly suppressed growth upon karonudib treatment
(see figure on previous page)
Fig. 1 A patient-derived xenograft clinical trial reveals a heterogeneous response to karonudib. a Schematic overview of the experimental
setup. Tumor biopsy from melanoma patient was serially transplanted twice in mice before being transplanted in mice treated with either karonudib
or vehicle. For each patient, there was one mouse per treatment group, which was treated for 18 days before tumors were harvested and processed.
Each tumor was snap-frozen for RNA analysis and embedded in paraffin for immunohistochemical straining. b Waterfall plot revealing the
heterogenous response to karonudib. The samples are divided in three response groups, progression (blue), suppression (yellow), and regression (red).
For treatment response catagorization, see Materials and methods. Comparison of average (±SEM) growth speed of karonudib treated vs. vehicle
treated PDXes for (c) progression group, d suppression group, and e regression group. Individual growth curves are shown in supplemental figures S2-
S4. f Kaplan–Meier graph showing the comparison of probability of progression-free survival in karonudib-treated mice (based on tumor doubling
time) for the three response groups (see Materials and methods for criterion), Mantel–Cox test used for statistical analysis. g Quantification of
immunohistochemical staining for the proliferation marker Ki-67 in vehicle vs. karonudib-treated PDXes, Student’s t test showing statistically significant
difference between the two groups (p= 0.0476). h Images of the xenograft sections stained with Ki-67 and used for the quantification in (g)
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Fig. 2 Karonudib has cytotoxic effect, irrespective of melanoma driver mutations. a Oncoprint showing melanoma hot-spot mutations found
in three response groups. Transparent colors indicate low confidence variants (Materials and methods). b, c Volcano plots showing differentially
expressed genes between the progression group and (b) suppression group, and (c) regression group
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correlated significantly (p= 0.03) to lower amount of Ki67
positive cells compared to the vehicle-treated mice in the
suppression group, as analyzed with immunohistochem-
istry (Fig. 1g, h).
Karonudib has cytotoxic effect on melanoma tumors,
irrespective of genotype
To investigate if the cytotoxic effect of karonudib was
dependent on the genotype, the vehicle tumors were RNA
sequenced and the mutation profile of the samples were
analyzed. This analysis revealed BRAF and NRAS muta-
tion in 65% (20/31) and 35% (11/31) of the samples,
respectively. Comparison of the mutation profile between
the response groups revealed that karonudib has cytotoxic
effect in melanoma PDXes, irrespective of the presence of
the genotype of the most common driver genes in mela-
noma, although a trend for an association between
mutation in DDX3X and the regression group was
observed (Fig. 2a and Supplemental figure S5A). However,
the mutations in DDX3X were difficult to interpret, since
these can be spread throughout the coding sequence and
could possibly also arise by RNA editing.
Further investigation of the DDX3X mutation revealed
increased PFS for karonudib-treated PDXes harboring the
mutation when compared to the wild-type PDXes, even
though not statistically significant (Supplemental fig-
ure S5b). Also, three different DDX3Xmissense mutations
were revealed (Supplemental figure S5c and Supplemental
table S2). To investigate if the impairment of the DDX3X
protein had functional relevance when treating tumor
cells with karonudib, the melanoma cell line MML-1 was
transfected with a siRNA targeted against DDX3X and the
cells treated with karonudib. A statistically significant
lower expression of DDX3X was observed in the siDDX3X
-transduced cells compared with the control-transduced
cells (p= 0.0003; Supplemental figure S5d). DDX3X
knockdown had a cytotoxic effect, and only 40% of the
cells were alive 36 h after transfection (p < 0.0001; Sup-
plemental figure S5e). When the DDX3X siRNA-
transfected cells were treated with increased concentra-
tion of karonudib, a reduced number of live cells was
observed when treated with 0.05 µM karonudib compared
with the control (adjusted p value= 0.0002) (Supple-
mental figure S5f).
High expression of ABCB1 identified as a potential
resistance biomarker
To screen for a predictive or a resistance biomarker for
karonudib treatment, the association between the gene
expression profile of the samples and response groups was
investigated. Differential gene expression analysis was
performed using the RNA-sequencing data from the
vehicle-treated samples (for information regarding total
reads per sample, see supplemental table S3). Comparison
of the progression group to the suppression and the
regression groups revealed differentially expressed genes,
one of which was ABCB1 (Fig. 2b, c and supplemental
table S4). Although highly expressed only in two of the
samples in the progression group (p= 8.52*10−5 and q=
0.049 compared to the suppression group), it was of
interest, since it encodes the multi-drug resistance (MDR)
pump, also known as the p-glycoprotein pump (p-gp)
(Fig. 3a).
To address the functional importance of high ABCB1
expression, we transduced the melanoma cell line SK-
MEL-2 with either an ABCB1-expressing virus or a con-
trol virus. Using quantitative real-time PCR, we observed
statistically higher expression of ABCB1 in the ABCB1-
transduced cells, compared to the control (p < 0.0001)
(Fig. 3b). Furthermore, we verified that the high mRNA
expression was translated to protein level, using flow
cytometry analysis (Fig. 3c). The pumping activity of p-gp
pumps can be followed by flow cytometry analysis of the
p-gp substrate Rhodamine 123. Cells with functional
pumps cultured in the presence of the substrate will pump
out Rhodamine 123 and become negative for the stain
over time. Our observation revealed high efficiency of the
ABCB1-expressing melanoma cells to pump out Rhoda-
mine 123. This activity could be inhibited with the p-gp
pump inhibitor Elacridar (Fig. 3d). When treating the
ABCB1-expressing cells with increasing concentration of
karonudib, statistically significant less cytotoxic effect was
observed for the ABCB1-expressing cells compared with
the control cells (adjusted p value < 0.001). This protective
(see figure on previous page)
Fig. 3 High ABCB1 expression as a resistance biomarker. a A waterfall plot showing treatment response for each of the PDX sample (see criterion
in Materials and methods). Bars are color coded according to expression level of ABCB1 in the vehicle-treated PDXes, blue= 0–99 normalized reads,
yellow= 100–1000 normalized reads, and red= >1000 normalized reads (for normalization method used see Materials and methods). b Quantitative
analysis of ABCB1 expression in SK-MEL-2 cells after transduction with an ABCB1-expressing virus, compared with the control virus (±SD) (p < 0.0001),
as analyzed with qRT-PCR. c Quantitative analysis of protein expression in the same cells, as b, analyzed with flow cytometry. d Quantitative analysis
of activity of p-gp pumps using the p-gp substrate Rhodamine 123, as analyzed using flow cytometry, cells either treated with the p-gp inhibitor
Elacridar (1 µM) or DMSO. e SK-MEL-2 cells transduced with ABCB1-expressing virus or control virus, treated with different concentrations of
karonudib in combination with 0.1 µM Elacridar or DMSO for 48 h. Cells analyzed using flow cytometry, and the data shown as average of triplicate
(±SD). Statistically significant rescue effect was observed when SK-MEL-2ABCB1 cells were treated with 0.5 µM karonudib (adjusted p value 2.6*10−8). f
Immunohistochemical staining of ABCB1 in vehicle and karonudib-treated xenografts from the progression group
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effect could be reversed by using the p-gp pump inhibitor
Elacridar (Fig. 3e). Finally, to assess if karonudib treat-
ment affects ABCB1 expression or causes selection of
ABCB1 high expressing cells, immunohistochemical
staining of biopsies from four PDXes with high and one
with low expression of ABCB1 mRNA (Fig. 3a) was
performed. Only one PDX (M150330) showed somewhat
higher expression of ABCB1 after karonudib treatment,
suggesting that this is not a common mechanism of
acquired resistance (Fig. 1f). Taken together, the data
show that high expression of p-gp pumps can make cells
less sensitive to karonudib treatment.
Fig. 4 Karonudib treatment does not hamper T-cell-mediated anti-tumor immunity. a Quantitative analysis of the degranulation marker CD107
on TILs from patient sample M151002 grown with or without autologous tumor cells and with or without karonudib, data shown as average of
triplicates (±SD). b Concentration of IFN-gamma in the media of the M15002 tumor cells cultured with or without autologous TILs and with or
without karonudib. The ELISA data are shown as average of triplicates (±SD). c–e Size or luminescence signal of PDX tumors treated with vehicle
(black), karonudib (red), injected with autologous TILs (blue) or karonudib+ TILs (green), data are shown as average of four mice (±SEM). f B6 mice
bearing tumors established from B16 mouse melanoma cell line, treated with either vehicle, CTLA4 antibody, karonudib, or combination of CTLA4
antibody and karonudib. Data in (f) shown as average tumor size of four mice (±SEM)
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Karonudib treatment does not impair the T-cell-mediated
anti-tumor response
Immunotherapy has recently proven to be an efficient
treatment for patients suffering from metastatic cuta-
neous melanoma. New targeted therapies or che-
motherapies therefore need to spare the effector cells,
primarily cytotoxic T cells, if used in combination with
immunotherapy. To inform on the potential usefulness of
karonudib in the immune therapy era, we investigated if
karonudib would affect the anti-tumor activity of cyto-
toxic T cells. First, we expanded tumor-infiltrating T
lymphocytes (TILs) from patient biopsy M151002 and
then added them to short-term cultures of tumor cells
from the same patient in the presence or absence of
karonudib. This resulted in degranulation of the T cells, as
measured by increased CD107 positive cells (Fig. 4a) and
increased secretion of IFN-gamma (Fig. 4b) when TILs
were co-cultured with autologous tumor cells for 24 h.
Reassuringly, no significant decrease was observed when
the cells were cultured in the presence of karonudib. To
test if this would cause anti-tumor effects in vivo, we used
our recently developed method to develop immune
humanized PDX models (PDXv2)9. PDX-generated
M151002 tumor cells were injected in NOG mice or
NOG mice, transgenic for human IL2 (hIL2-NOG). When
tumor growth was confirmed, we injected TILs in the
hIL2-NOG mice, and subsequently treated half of the
NOG mice and half of the hIL2-NOG mice with kar-
onudib. Again, karonudib treatment did not impair the
anti-tumor activity of TILs. The response was assessed by
both measuring the physical size of the tumors (Fig. 4c)
and the bioluminescence from the luciferase-expressing
tumor cells (Fig. 4d, e). Furthermore, we tested if kar-
onudib impaired the anti-tumor effect of anti-CTLA-4
treatment in immunocompetent mice bearing mouse
melanoma tumors. We transplanted B16F10 mouse mel-
anoma cells subcutaneously in B6 mice and treated with
vehicle, anti-CTLA-4, karonudib, or combination of
CTLA-4 and karonudib. Tumors on mice treated with
anti-CTLA-4 antibody alone showed good responses by
suppression of tumor growth, which was not impaired by
the combination treatment with karonudib (Fig. 4f).
Taken together, this indicates that karonudib does not
have obvious negative effect on T-cell-mediated anti-
tumor effect.
Conclusion
Here we show that the previously published anti-cancer
effects of karonudib in one melanoma PDX4 can be
demonstrated in a larger cohort of animal models.
Importantly though, we also demonstrate that some
models remain unaffected by karonudib, suggesting
resistance mechanisms. The data therefore confirm the
utility of PDX trials when preclinically assessing small
molecule inhibitor efficacy10, 11. In the clinic, the response
evaluation criteria in solid tumors (RECIST) criterion is
used to evaluate the treatment response12. In a recent
PDX trial paper and in a second paper re-analyzing the
same data, a modified RECIST criterion is used to define
the response groups10, 11. When using the RECIST cri-
terion, the inherent growth speed of the tumor is not
taken into account when assessing the treatment
response. Since we used a matching vehicle-treated PDX
for all karonudib-treated PDXes, it allowed us to take the
inherent tumor growth speed into consideration when
categorizing samples in the response groups (treated/
control). We observed that the tumors with the fastest
inherent growth speed also exhibited the biggest size
difference between the treated and the untreated tumors.
Using normal RECIST, these tumors would have been
categorized as stable disease. Our study shows that such a
stable disease would have clear clinical benefit in com-
parison to no treatment.
Interestingly, we observe that karonudib has anti-tumor
effect on melanoma PDXes, irrespective of mutation sta-
tus of major melanoma driver genes. Earlier work sug-
gested that oncogenic KRAS-driven tumors would benefit
from MTH1 expression13–15. We did not see any differ-
ence in sensitivity between BRAF- and NRAS-mutated
tumors. This either means that the same rules do not
apply in melanoma, that oncogenic KRAS and NRAS
differ or that the mechanism of action of karonudib
extends outside MTH1 inhibition, e.g., the proposed
microtubule disruption caused by inhibitors of the same
class as karonudib5–7.
We also observed that four PDX models in the cohort
exhibited a mutation or variant in DDX3X. The fact that
all these models were in the regression group was inter-
esting. DDX3X is an RNA-binding protein and when
mutated, it is known to impair global translation and
induce stress granulation assembly16. Stress granules are
normally formed in cells under acute stress, for example,
oxidative stress, UV irradiation, and heat shock. Fur-
thermore, it has been shown that cells treated with
microtubule-targeting agents show difference in size and
location of stress granules17. However, we cannot, at this
time, state that DDX3X mutation is a predictive bio-
marker due to two reasons: First, the functional analysis
hampered by DDX3X knockdown was lethal and there-
fore only additive to the effects of karonudib. Second,
none of the observed DDX3X mutations have been
described before, meaning that additional analyses are
needed to draw a firm conclusion.
One of the aims of this study was to identify a predictive
biomarker of response. High expression of p-glycoprotein
(p-pg) is a well-known drug-resistance mechanism18. P-gp
pumps are transmembrane proteins, which act as ATP-
dependent drug-efflux pumps. They are known to
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recognize and excrete compounds, even compounds the
cell has not been exposed to before19. Furthermore, it has
been shown that MDR genes such as ABCB1 and ABCG2
are dispensable for mouse development20, suggesting that
they might be suitable targets. Here, we observe that high-
expressing ABCB1 cells are less sensitive to lower con-
centrations of karonudib than the control cells, which
could be reversed by co-treating the cells with Elacridar (a
known p-gp pump inhibitor18), establishing that kar-
onudib is a p-gp substrate. That observation could be
useful in the clinical setting for patients known to bear
tumors with high p-gp pump expression, for example, in
patients who have acquired resistance to chemotherapy21.
Also, it raises the possibility of using p-gp pump inhibitors
in combination with karonudib in the clinic. That com-
bination treatment could be especially beneficial for
melanoma patients, given the high expression of p-gp
pumps in the blood–brain barrier, and that 10–20% of
melanoma patients exhibit brain metastases.
It is likely that current treatment regiments only will
cause durable responses or cures in subgroups of patients
with melanoma. Current melanoma treatment includes
both targeted therapy (BRAF and MEK inhibitors) as well
as immune therapy (checkpoint block antibodies directed
against PD1, PD-L1, and CTLA-4)2. Since durable
responses to both these treatments have been correlated
to abundance of tumor-infiltrating lymphocytes22, 23, it is
imperative that novel treatments do not block the anti-
tumor immunity. Hence, the fact that karonudib neither
hinders adoptive T-cell transfer nor anti-CTLA-4 treat-
ment in mice suggests that it can be used in combination
with immune therapy.
Future use of karonudib is dependent on not only that it
survives phase I clinical testing, but also that it causes
clinically meaningful responses in patients. Most of the
PDX models tested here reach a clinical response of stable
disease. If this is reproduced in patients, combination
treatments might be used to achieve tumor regression.
Finding the right drug combinations (besides drug-pump
inhibitors) is under active investigation.
Materials and methods
Ethical approvals
All experiments using patient material or research ani-
mals were performed according to the ethical approval
provided by the Regional Human Ethics Board of Västra
Götaland, Sweden #288-12 or by the Animal Ethics Board
#2016-34, respectively.
Patient material
All samples were obtained from patients who had pro-
vided informed consent and were treated at the Depart-
ment of Surgery, Sahlgrenska University Hospital,
Gothenburg, Sweden.
Study design of the patient-derived xenograft clinical trial
Patient-derived xenografts were established from 31
metastatic melanoma patients, as previously described8.
Each patient sample was transplanted in three mice.
Palpable xenografts were measured three times weekly
using a caliber and assigned to their treatment groups
when they reached 50–100mm3. The first mouse to reach
the inclusion criterion was assigned to the karonudib
treatment group, the second to the vehicle group, and the
third mouse was excluded, utilizing the one mouse per
patient per treatment group setup previously described10.
Each mouse was treated for 18 days with either 90 mg/kg
karonudib or the vehicle (20% w/v HPβCD in sodium
acetate buffer pH 4.6) twice a day, three times per week.
Treatment response was assessed by monitoring changes
in tumor volume of the treated mouse and comparing to
the tumor volume of the vehicle-treated mouse (treated/
control (%)) using the following formulas:
tumor volume mm3ð Þ ¼ shorter diameter
2 mmð Þ ´ longer diameterðmmÞ
2
and
T=C %ð Þ ¼ TiT0
CiC0
where Ti and Ci represents tumor sizes
at the end of the treatment and T0 and C0 represents
tumor sizes at treatment start. Response criterion was as
follows; progression if T/C > 50%, suppression if T/C=
50–0%, and regression if T/C < 0%. Weight of mice and
tumor size were measured three times per week. After
18 days, mice were sacrificed and the tumors harvested
and weighted. Tumor pieces were processed and pre-
served as snap-frozen or embedded in paraffin for RNA or
protein analysis, respectively.
RNA analysis
Tumors were dissociated using a Bullet Blender® and
RNA was extracted using Nucleospin RNA kit (Machery-
Nagel). Quantitative RNA analysis was conducted by
synthesizing cDNA (iScript, BioRad) from the extracted
RNA, which was quantified by qPCR (Kapa Biosystems).
Primer sequences are available upon request. The
extracted RNA was also used for RNA sequencing (Sci-
LifeLabs NGS Core Facility, Stockholm, Sweden). Library
was prepared using the Illumina TrueSeq with poly-A-
selection and sequenced in a HiSeq 2500.
Immunohistochemistry
Fresh tumor pieces were fixed in 4% formalin, dehy-
drated, and embedded in paraffin. Next, 5-μm sections
were made, mounted on glass slides, and dried over
night at 37 °C. Rehydration and antigen retrieval
were performed by pressure cooking in citrate buffer.
Staining was performed with an auto-stainer (Autostainer
Link 48, Dako). Primary antibody staining was done
for 60min at room temperature, secondary for 20min,
and horseradish peroxidase staining for 20min. DAB
Einarsdottir et al. Cell Death and Disease  (2018) 9:810 Page 9 of 12
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(Diaminobenzidine) staining was used to stain the DNA
and counterstaining was done using hematoxylin. Finally,
the sections were dehydrated, mounted with Pertex, and
imaged.
Antibodies
Anti-human Ki-67 antibody (DAKO) and anti-human
ABCB1 antibody (Cell Signaling #13342).
Compounds
Karonudib (TH1579) was synthesized at the Karolinska
Institute according to previously published synthesis
schemes (WO2015187088A1). Elacridar (GF120918) was
bought from Selleck Chem (selleckchem.com).
Bioinformatics
Alignment and pre-processing for variant calling
Raw reads were aligned to a combined human (hg19)
and mouse (mm10) reference using STAR24 2.5.2b with
default parameters. The index file for STAR was aug-
mented with splice junctions from a concatenated human
GENCODE25 version 17 and mouse GENCODE version
M726 reference annotation. Reads mapping to human and
mouse chromosomes, respectively, were then extracted
using Samtools27 0.1.19. For reads mapping to both
organisms, Samtools and the FilterSamReads module of
Picard 1.109 (github.com/broadinstitute/picard) were
then used to discard those that were not primary align-
ments with respect to the human reference. This strategy
was motivated by the desire to minimize false positives in
variant calling due to potential mouse contamination in
the tumor samples.
Variant calling and filtering
Single-nucleotide variants and indels were called by first
using the mpileup module of Samtools with disabled BAQ
computation, a supplied list of regions for the genes of
interest as well as the hg19 reference. The resulting out-
put was then supplied to the VarScan28 2.3.9 tool mpi-
leup2cns, for which the settings “min-coverage 2”, “min-
reads2 2”, “min-var-freq 0.01”, and “min-avg-qual 15”
were used. This very sensitive option was motivated by
the desire to minimize the risk of false negatives owing to
the lowly expressed genes and allelic imbalance, combined
with the small list of genes being considered for calling.
To further increase sensitivity, the two steps above were
performed first on each sample individually, and then on a
combination of all samples. The resulting call sets were
then merged using the CombineVariants module of
GATK29 3.3.0.
Variant annotation was then performed using ANNO-
VAR30, cross-referencing the databases RefGene31, COS-
MIC32 v79 and dbSNP33 v138 with flagged somatic and
clinically associated variants removed, ESP6500 (http://
evs.gs.washington.edu/EVS), 1000 Genomes34 (August
2015). Synonymous variants, variants in non-exonic
regions and those with an entry in the non-flagged
dbSNP 138 database were then discarded. For increased
specificity, only known COSMIC variants in oncogenes
were retained. For tumor suppressors, non-COSMIC
variants were also considered, provided that the variant
was not present in the ESP6500 or 1000 Genomes data-
bases. This was motivated by the fact that tumor sup-
pressors are more likely to be subject to novel loss of
function mutations. Additional manual inspection of
variants was performed in IGV35, and novel mutations
adjacent to homopolymer repeats or those only occurring
at the ends of reads were discarded. Two additional
potential mutations at known or recurrently mutated
sites, although with very few supporting reads (2, 1, and 2
respectively), were added for samples M130111 (NRAS),
M140602A (NRAS), and M120511B-2 (DDX3X) after
visual inspection. The final set of mutations were visua-
lized with Maftools36 R package.
Gene expression analysis
Differential expression analysis was performed in R,
using the DESeq237 package (default parameters), after
first filtering out the unexpressed genes. Batch effects
were accounted for in the DESeq2 regression model, since
the samples M130128A, M130204B, M141204, M150313,
and M160212 were sequenced at a different date. To
visualize gene expression values, normalized and batch
corrected counts were derived using the “removeBatch-
Effect” function in the limma38 package, based on values
obtained with the “variance stabilizing transformation”
DESeq2 method. Gene set enrichment analyses were
performed on gene lists ranked by the log2-fold changes
estimated by DESeq2 using FGSEA39, based on the
MSigDB40 “Canonical pathways” gene set. A minimum
gene set size of 25 and a maximum of 500 was specified
and 1 million permutations were demanded.
Cell lines
The melanoma cell lines SK-MEL-2 and MML-1 were
purchased from the Cell Lines Service GmbH (Eppelheim,
Germany), and HEK-293T was purchased from ATCC,
Manassas, VA). They were cultured in 37 °C and 5% CO2
in the presence of DMEM-F12 (SK-MEL-2), RPMI1640
(MML-1), or DMEM media (HEK-293T) (Gibco), sup-
plemented with 10% fetal bovine serum (Gibco) and
Gentamycin (Thermo Fisher Scientific, Waltham, MA).
Transfection
MML-1 cells were transfected with a pool of five dif-
ferent siRNAs against DDX3X (SMARTpool, Dharma-
con) in the presence of DhermaFECT (Dharmacon).
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Cell cycle analysis
Harvested cells were re-suspended in modified Vinde-
lövs solution (20 mM Tris, 100mM NaCl, 1 µg/mL 7-
aminoactinomycin D (7-AAD), 20 µg/mL RNase, and
0.1% nonidet P-40, adjusted to pH 8.0). The samples were
analyzed using a BD Accuri C6 flow cytometer.
Quantification of ABCB1 protein expression in vitro
Harvested cells were fixed and permeabilized (Fixa-
tion/Permeabilization solution, BD Bioscience). Next,
the cells were stained with monoclonal rabbit ABCB1
antibody (Cell Signaling #13342) followed by staining
with a secondary anti-Rabbit FITC (DAKO F0205). The
stained cells were analyzed using a BD Accuri C6 flow
cytometer.
Analysis of p-gp pump activity
Cells were grown in the presence of 200 ng/mL Rho-
damine 123 for 60 min with or without Elacridar (1 µM).
After incubation, the cells were washed with PBS and
cultured for another 90min in fresh medium with or
withour Elacridar (1 µM). Cell were harvested and re-
suspended in PBS and analyzed with a BD Accuri C6 flow
cytometer.
Flow cytometry sorting of ABCB1 expressing cells
Cells were cultured in the presence of Rhodamine
123 (200 ng/mL) for 60min. The harvested cells were
sorted based on negative Rhodamine 123 signal, using
Facs Aria IIIµ.
Virus production and transduction
The calcium phosphate precipitation method was
used to produce retroviruses by transfecting HEK-293T
cells with the following plasmids; pHaMDRwt (kind
gift from Michael Gottesman, Addgene plasmid
#10957)41 and MSCV-IRES-PURO. Target cells were
transduced over night and analyzed 72 h after
transduction.
Degranulation assay
TILs (tumor infiltrating lymphocytes) were extracted,
cultured, and expanded in vitro by culturing primary
tumor pieces in the presence of IL2. Next, the TILs and
autologous tumor cells were incubated separately over-
night with 0.5 µM karonudib or DMSO (1:20000), after
which 3*105 TILs and 1*105 tumor cells were plated
together in a 96 well V-bottom plate and cultured with
monoclonal antibody for CD107a (LAMP-1)-APC human
(clone: REA792) (Milteny Biotech). After the 6-h incu-
bation, cells were washed once and re-suspended in
MACS buffer before the surface expression of CD107 was
determined by flow cytometry using a BD Accuri C6 flow
cytometer.
Measurement of IFN-gamma
IFN-gamma concentration in cell culture medium was
measured using an enzyme-linked immunosorbent assay
(ELISA) (Diaclone).
PDXv2 mouse model
The method of making PDXv2 mouse models has been
previously described9. Briefly, patient-derived tumor
sample (M151002) was transduced with a pHAGE-luc-
GFP virus and transplanted subcutaneously on the flanks
of the immune deficient mice. Once tumor growth was
confirmed by bioluminescence measurements (Perki-
nElmer IVIS Lumina III XR), the mice were separated in
four treatment groups of four mice receiving either kar-
onudib or vehicle (same concentrations and dosing
schedule as in the pre-clinical PDX trial) with or without
TILs (one injection of 20*106 TILs). Tumor growth was
followed by caliper and bioluminescence measurements.
Statistical analysis
Graphs and statistical testing were generated using
GraphPad Prism, error bars on growth curves are shown
as standard error of mean (SEM), and other error bars are
shown as Standard error of mean (SD). Student’s t test
was performed, where statistically significant P value was
indicated as; *P < 0.05, **P < 0.01, ***P < 0.001, or ****P <
0.0001.
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